To date, there is no direct mechanistic data to validate these models for MDS, but studies in analogous humanized and CD123-targeting systems show T-cell activation, IFN-γ release [38], and preferential targeting of CD123+ blasts over normal CD34+ progenitors [39]. This evidence concerns the gene CD34 and myelodysplastic syndrome.